Company page

Cabaletta Bio, Inc.

Cabaletta Bio, Inc. is a public biotechnology company based in the United States, focused on developing innovative cell therapies for autoimmune diseases. The company is traded under the ticker symbol CABA and has a market capitalization of approximately $438.6 million. Cabaletta Bio is committed to advancing its research and development efforts in the field of immunotherapy.